Prevalence and predictive factors associated with sustained remission in SLE: a systematic review Authors: Rym Abida, Anisur Rahman Published: 2025 ABSTRACT AbstractObjectiveThe question of sustained remission in SLE has been highlighted recently following data published on the use of chimeric antigen receptor-T cell therapy in SLE. With the review, we wanted to investigate the prevalence of sustained remission of 2 years or more in SLE with the current available treatments and to assess the predictive factors associated with this state.MethodsA systematic review of Embase via Ovid and Medline via Ovid was performed. We considered articles of adult patients with SLE that report the prevalence and/or the predictive factors of sustained remission in SLE. We considered that the latter state is sustained if it was for 2 years or more.Results20 studies were included for final review. The definition of remission was different between studies, and most authors considered different types of remission based on the serological activity and the current therapy. The prevalence of long-term remission was different across studies depending on the definition used. It ranged from 0.3% to 63%. Older age at diagnosis, lower disease activity at baseline and the absence of renal disease involvement were the most commonly found factors likely associated with sustained remission.ConclusionLong-term remission is an achievable state in SLE with current treatment. Studies report a striking heterogeneity in the current prevalences. This is likely to be caused by the lack of objective measures to confirm the state of sustained remission in SLE.Keywords: Lupus Erythematosus, Systemic; Prevalence; Risk Factors WHAT IS ALREADY KNOWN ON THIS TOPIC The use of chimeric antigen receptor-T cell therapy in the context of SLE has been a groundbreaking approach, as it showed that sustained remission is an achievable target in SLE. While some of our patients also go into this state with the current available treatments, data on this group of patients remains limited. The use of chimeric antigen receptor-T cell therapy in the context of SLE has been a groundbreaking approach, as it showed that sustained remission is an achievable target in SLE. While some of our patients also go into this state with the current available treatments, data on this group of patients remains limited. WHAT THIS STUDY ADDS There is a striking heterogeneity in the definition of sustained remission despite the most recent international guidelines. The large variation in reported prevalences also underscores the different attitudes of prescribers with regard to decisions to taper or discontinue SLE-specific treatments. There is a striking heterogeneity in the definition of sustained remission despite the most recent international guidelines. The large variation in reported prevalences also underscores the different attitudes of prescribers with regard to decisions to taper or discontinue SLE-specific treatments. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY There is an urgent need to find objective markers to better define patients in long-term remission and potentially support prescribers with the decision of stopping or weaning down SLE-specific medication. There is an urgent need to find objective markers to better define patients in long-term remission and potentially support prescribers with the decision of stopping or weaning down SLE-specific medication. Introduction Although rare, SLE is one of the most known autoimmune conditions, affecting approximately 1 in 1000 people in the UK.1 It usually follows a relapsing-remitting pattern with several episodes of flares between episodes of quiescence. This condition presents a striking heterogeneity, and it is still difficult to predict the organs that will be involved during a flare, its severity and the duration of quiescence periods for the same patient. The latter is an important factor to consider in the overall management of patients with SLE because of the direct link between remission and disease outcomes: Two recent systematic reviews have found that remission in SLE lowers the mortality risk as well as the risk of damage and of cardiovascular events while promoting a better quality of life.2 3 Zen et al have shown that, beyond the threshold of 2 years, the longer the remission, the better the disease outcomes.4 The question of sustained or durable remission has been highlighted recently by work from Erlangen5 on results obtained using chimeric antigen receptor-T cell (CAR-T) therapy in patients with SLE. Though only a small number of patients have been reported so far, the results raise the possibility of long-term serological and clinical remission off treatment following CAR-T cell treatment. It is therefore important to consider how often sustained remission is achieved with current treatments. A previous retrospective study done at University College Hospital, which included 564 patients with SLE followed up for over 40 years, found that 15% achieved durable complete remission for a period of 3 years, 73% of whom maintained this state for 5 years or more.6 Similar results were found in the Italian cohort published by Zen et al.4 It is still unclear why these patients go into this long-term remission and what promotes its sustainability. In 2022, Yang et al3 published a systematic review of 41 studies investigating the prevalence of remission in SLE and reported a striking heterogeneity in defining remission across studies, which translated into a prevalence ranging from 42.4% to 88% of remission lasting for 1 year and from 21.1% to 70% if remission lasts at least 5 years. This study, however, did not focus on sustained remission and did not include studies carried out since an international task force working on the definition of remission in SLE (DORIS) published their final recommendations defining remission in SLE. This definition requires a clinical SLE Disease Activity Index 2000 (SLEDAI-2K) of 0, a Physician’s Global Assessment (PGA) <0.5 and depending on the current therapy and the serological activity, they defined7 8: Clinical remission on treatment if the patient is receiving a stable medication, including antimalarials, steroids (glucocorticoids (GC) ≤5 mg/day), immunosuppressive and/or biological drugs. Serological activity is allowed. Clinical remission on treatment if the patient is receiving a stable medication, including antimalarials, steroids (glucocorticoids (GC) ≤5 mg/day), immunosuppressive and/or biological drugs. Serological activity is allowed. Clinical remission off treatment if the patient is not on any steroid, immunosuppressive or biological treatment. Antimalarial treatment is, however, allowed. Clinical remission off treatment if the patient is not on any steroid, immunosuppressive or biological treatment. Antimalarial treatment is, however, allowed. Complete remission is achieved if the patient is in clinical remission off treatment with no serological activity. Complete remission is achieved if the patient is in clinical remission off treatment with no serological activity. A number of new studies have been published after 2021 and, in particular, have used the DORIS criteria to define remission in their SLE cohorts. Therefore, we felt that an updated systematic analysis to include this important new work would be valuable. In this study, we wanted to focus on the prevalence of sustained remission in SLE and to assess the predictive factors likely to be associated with it. Methods This systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 guidelines.9 Patients and the public were not involved in the study. An initial scoping search was performed using PubMed, the Cochrane Library and the PROSPERO database and resulted in 11 articles. Information sources and search strategy The systematic search was conducted using Embase via Ovid and Medline via Ovid. Databases were searched from inception until 8 July 2024. Keywords used were (lupus or lupus erythematosus or systemic lupus erythematosus), (remission or quiescence or inactivity or activity or flare) and (sustained or maintained or prolonged or durable) (see online supplemental file 1). A supplementary search was also conducted from the reference lists of the systematic reviews included. Eligibility criteria We considered publications involving adult patients aged 18 years or over with SLE. Studies about juvenile SLE and other autoimmune conditions were excluded. We looked at studies reporting prevalence and factors associated with prolonged remission. We considered that remission is prolonged if it is maintained for 2 years or more. Studies included could be descriptive (cohort studies or case-control studies) or clinical trials or case series if relevant to our study objectives. Case reports, literature reviews, editorials and studies on animal models were excluded. When a given cohort was described in more than one publication, we examined all full texts linked to this cohort and only included the most recent or the most relevant publication addressing our specific research questions. Publications were only considered if they were written in English or French. Search strategy The search strategy was constructed by RA and AR and was peer-reviewed by a UCL librarian according to Peer Review of Electronic Search Strategy guidelines.10 Details of the search strategy can be found in online supplemental file 1. RA deduplicated the results using an automation tool called the Systematic Review Accelerator.11 Additionally, RA manually checked the reference lists of the included studies and conducted the supplementary search. Selection process RA screened the titles and abstracts against the inclusion criteria. For all eligible articles after initial screening, full texts were retrieved by RA and independently reviewed by AR and RA, and discrepancies were resolved. The citation search was screened by RA. Data collection process A data extraction sheet was designed and optimised using three pilot articles. The final report included the study design, methodology, definition of remission, duration of remission and characteristics of patients. The variation of definitions of remission across studies was expected as a potential bias risk. Details on the different items used to define remission in each study were added to the data collection report. Results of prevalences were expressed in percentages. No assumptions were made about any missing or unclear information. Registration This review was not registered, as it did not involve interventional studies. Results A total of 7635 studies were identified. Duplicates, pre-prints and unsuitable studies by title and abstract alone were excluded. Of the remaining 138 abstracts, 20 were included in the review as detailed in figure 1 (flow chart as per PRISMA guidelines9 12). All articles assessed for eligibility were in English—the search did not identify any relevant work in French. A supplementary search from the reference list of the existing systematic review did not find additional reports. Flow chart of included studies as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Definition of remission The definition of remission was different in each study, and most authors defined different types of remission. In summary, the definition of remission involved four separate items: the clinical activity, the current treatment, the serological activity and the PGA, as shown in online supplemental table S1. Remission groups were defined using at least two of the four above-mentioned items in all studies except for one study led by Gyori et al.13 In this study, two groups of remission patients were defined: one group had a modified SLEDAI=0, and the other group had a PGA=0.13 Only 5 out of 20 studies used all four items.814,17 The PGA was the least used score to define remission (6/20), and all authors agreed that it should be <0.5 as per DORIS guidance.78 14,18 The clinical activity item was used in all studies, although defined differently depending on the score used: clinical SLEDAI-2k,813 15,28 clinical Safety of Estrogens in Lupus Erythematosus National Assessment - SLE Disease Activity Index (SELENA-SLEDAI)14 or British Isles Lupus Assessment Group (BILAG).6 21 In essence, patients should not have any overt active clinical or biological manifestation related to SLE. Serological activity refers to increased levels of anti-double-stranded (ds) DNA antibodies and/or low titres of complement C3 and/or C4. It was used in eight studies to differentiate patients in clinical remission from those in complete remission.68 14,17 27 28 The assays used to measure these levels were not mentioned in all the studies. Current treatment was also used in most studies to define groups of patients in remission on treatment and those off treatment. Six studies have considered patients off all medication, including hydroxychloroquine,14 15 22 23 25 29 whereas seven studies have accepted possible ongoing hydroxychloroquine treatment in their ‘off all medication’ group.68 16 17 26,28 Two studies have compared patients in remission off all SLE-specific medication against patients on hydroxychloroquine only. Two other studies have defined a separate group of patients off GC but who might be on a stable dose of antimalarials and immunosuppressive treatment. Duration of long-term remission The duration needed to define long-term remission was different from one study to another. Five studies used different timelines ranging from 2 to 10 years to define different groups of patients in long-term remission. For the other studies, sustained remission was defined as remission for 2 years or more in three studies, 3 years or more in one study, 5 years or more in eight studies and 10 years or more in two studies. On the other hand, Gatto et al20 defined an average duration of long-term remission of 9.5 years (5.8–14.5). Prevalence of remission The prevalence of long-term remission was different across studies depending on how it was defined. It ranged from 0.3% to 63%. On the one hand, the highest prevalences were seen in patients in clinical remission on stable medication for 5 years or less and when serological activity was allowed. On the other hand, the lowest rates were mostly seen when serological activity was not allowed, and the duration of remission was 10 years or more. Predictive factors for long-term remission 12 studies have investigated the factors associated with sustained remission in patients with SLE, as shown in table 1. Table 1Factors associated with long-term remissionStudyFactorP valueRisk measure* 95% CI Durao-Carvalho et al6White ethnicity0.008HR 2.2751.244 to 4.163Age at diagnosis >32 years0.001HR 2.4391.459 to 4.076Absence of renal involvement0.023HR 2.3391.116 to 4.493No APS0.018HR 10.9941.521 to 79.451Fasano et al19Long-term HCQ0.03––5-year remission at baseline0.0003––Absence of serological activity0.0003––Absence of renal involvement0.01––Gatto et al20Older age at diagnosis0.006HR 1.0151.004 to 1.026HCQ0.03HR 2.7762.306 to 3.250Mycophenolate mofetil0.027HR 1.3961.039 to 1.874Jakez-Ocampo et al22Absence of inflammatory-type rash<0.001––Alopecia<0.001––Thrombocytopenia0.007––Older at diagnosis0.055––Lower SLEDAI at baseline0.001––Kasitanon et al25Age at diagnosis >25 years0.012HR 2.571.23 to 5.4HCQ0.044HR 2.81.4 to 5.57Mok et al14Older age0.004––Absence of leucopenia<0.001––Absence of thrombocytopenia0.005––Absence of renal involvement0.04––Absence of anti-Ro antibodies0.03––Absence of anti-La antibodies0.02––Absence of antiribonucleoprotein antibodies0.02––Nikfar et al15Serological remission0.001OR 7.584.37 to 18.42Time to remission <6 months0.032OR 5.121.15 to 22.72More than one flare0.002OR 0.070.02 to 0.36Pitsigavdaki et al18Cluster 2: serositis, thrombocytopenia and neurological disease–––Steiman26No dermatological involvement0.0004––No neurological involvement0.002––No pulmonary involvement0.0009––White ethnicity0.02––Lower SLEDAI at baseline0.02––Tani et al17Lower SLEDAI at baseline<0.001––Absence of joint involvement0.01––Absence of mucocutaneous involvement0.02––Tsang et al27Lower SLEDAI at baseline0.005––Fewer American College of Rheumatology criteria0.038––Absence of renal involvement0.008––Lower median prednisolone dose at baseline<0.001––Zen et al28Absence of glomerulonephritis0.004OR 2.381.32 to 4.29Absence of vasculitis0.017OR 4.951.33 to 18.37Absence of haematological abnormalities0.014OR 2.191.17 to 4.12*Risk measure added where available; OR and HR.APS, antiphospholipid syndrome; HCQ, hydroxychloroquine; SLEDAI, SLE Disease Activity Index. Factors associated with long-term remission Risk measure added where available; OR and HR. APS, antiphospholipid syndrome; HCQ, hydroxychloroquine; SLEDAI, SLE Disease Activity Index. From table 1, we notice that older age at diagnosis (4/12 studies), lower SLEDAI at baseline (4/12) and the absence of renal disease (3/12) are the most common factors associated with long-term remission. Experimental studies Two studies included in our review tried to investigate the deep immune phenotypes of SLE patients in long-term remission.21 23 In 2011, Iwata et al21 described the phenotypic changes of B and T cells of 10 patients with SLE 28 days and 2 years after receiving B-cell depletion therapy with rituximab. They found that patients who remained in sustained remission 2 years after therapy (n=8) had persistently low levels of plasma cells/naive B cells and memory B cells/naive B cells ratio compared with their levels before treatment (4.80±2.12 to 0.15±0.07, p<0.001 and 4.8±2.1 to 0.1±0.2, p<0.001, respectively). Authors also found a significant reduction of the percentage of memory T cells among the CD4-positive T cells (66.2±16.2% to 45.9±16.2%, p=0.0124) that remained low in patients in sustained remission. In 2021, Lima et al23 investigated the phenotypes of T cells present in 15 patients in clinical remission off all medication, including hydroxychloroquine, for at least 10 years and compared them to those of 15 patients with active disease and 29 healthy controls. Authors found that patients in sustained remission had higher ratios of T cell subtypes expressing markers of T cell exhaustion compared with active patients: T-box transcription factor TBX21 (median=0.20, IQR=1.74– 30.50 vs 1.68, IQR=0.4–­2.83; p<0.01) and eomesodermin (37.6, IQR=24.9–­53.2 vs 8.13, IQR=2.33–­20.5; p<0.001). Discussion The evolution from a symptom-based to a targeted approach and the adoption of the concept of treat-to-target therapy were introduced to the management of SLE in 2013 when an international task force published the first practice guidelines, confirming that remission should be the ultimate treatment target of SLE.30 Although it seems instinctively obvious, it is challenging to define remission in real practice given the large heterogeneity in disease presentation, course and severity. Efforts have been made during the last decade to standardise the definition of remission combining clinical and serological criteria. Different definitions of remission have been suggested,31 the latest being the DORIS task force that defined types of remission based on the clinical activity, the current medication, the serological activity and the PGA.7 In comparison to the systematic review by Yang et al,3 this paper includes references published since 2021 and some experimental papers, while excluding studies that did not investigate sustained remission and repeat studies on the same cohort. PGA in defining remission The rationale of adding PGA to the definition of remission was to increase sensitivity and assess clinical features not covered by the SLEDAI scoring system.7 Although this tool is helpful in assessing the patients’ overall status, it remains a subjective tool with a high interrater and intrarater variability.32,34 In 2020, an Italian study tested seven potential definitions of remission and their performance in predicting damage outcomes.35 Authors found that adding PGA <0.5 to the clinical-SLEDAI (c-SLEDAI) score to define remission led to decreased disease remission by 1.8 years/patient without altering the performance of c-SLEDAI in predicting disease outcomes. In this same cohort, authors found that among the 195 patients who had PGA ≥0.5 and c-SLEDAI=0, 157 (80.5%) presented non-specific patient-reported symptoms, mainly arthromyalgia, fatigue and low back pain.34 The authors concluded that PGA might not be a very useful tool in the setting of clinical remission since many symptoms that drive high PGA may not be caused by lupus disease activity. In 2022, a task force of lupus experts published a consensus aiming to standardise the use of PGA in the context of SLE.36 Authors recommended that patients should only be rated by experienced physicians, ideally by the same rater at each visit, which is not always possible in real-life settings. Serological activity Serological activity refers to the immunological items of the SLEDAI-2k score, which translates to high levels of anti-dsDNA antibodies and/or low complement C3 or C4 levels. This separates patients who are in complete remission, whether this is on or off treatment, and those who are in remission only clinically. The latter group is called serologically active clinically quiescent patients. Most of the studies included in our systematic review did not mention which assays were used to determine serological activity. This is important because we now know that the pathogenic effect of anti-dsDNA antibodies on lupus activity is different across antibody subclasses.37 Studies have, in fact, shown that the IgG subclasses of anti-dsDNA are directly linked to disease activity,37 while other studies suggest that the IgM subclass has potentially a protective role in lupus nephritis and is associated with lower cardiovascular events.38 In a similar context, a post hoc analysis of the BEAT-LUPUS trial (Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A randomized Controlled Trial) has found that patients carrying high levels of circulating IgA2 anti-dsDNA antibodies predicted clinical response to B cell depletion therapy. Exemplifying the difficulty of interpreting the concept of serological positivity across studies using different assays, we published a report describing the impact in our clinic of changing from an ELISA assay that measured both IgG and IgM subgroups of anti-dsDNA antibodies (DIASTAT ELISA assay; FDNA 100) to an IgG-specific ELiA (Phadia 2500 analyser; 14-5500-01).39 We found that some patients who were labelled serologically active with the ELISA assay were only IgM positive and therefore, they switched into the category of serological remission with the second assay. Therefore, the estimation of serological activity in published studies can be biased and could impact the prevalences seen above. Treatment The literature defines two types of remission, as shown in online supplemental table and as per DORIS guidance7 31: on and off treatment. Some authors allow the use of hydroxychloroquine in the ‘off treatment group’, while others focus only on groups of patients on or off GC. This would have been an effective standardised way to classify patients if all physicians had the same attitude towards prescribing and stopping SLE-specific medication. The literature is not conclusive regarding the time needed to stop treatment. A French clinical trial carried out in 2021 compared the relapse rate of patients clinically in remission after GC withdrawal with those kept on GC 5 mg/day40 and found the second group had a lower relapse rate using the SFI (3 patients vs 12; RR 0.2 (95% CI 0.1 to 0.8), p=0.012) and the BILAG index (1 patient vs 8; RR 0.1 (95% CI 0.1 to 0.9), p=0.013). The authors recommended that patients should be kept on long-term maintenance treatment with low-dose GC to prevent flares. Conversely, an Italian study carried out the same year found that GC withdrawal was a safe option in patients with SLE in remission and did not carry a higher risk of flare (p=0.81).19 This discrepancy in the literature is translated into daily practice by the heterogeneous attitudes of physicians and prescribers towards stopping the treatment. For this reason, we need to be cautious when interpreting the prevalences of groups of remission based on their current medication. Factors associated with sustained remission Among the studies investigating factors associated with sustained remission, a few have used multiple variable analysis to show statistical significance. Overall, it seems that patients who were diagnosed at an older age and presented with a mild disease at onset were more likely to reach the state of sustained remission. The effect of other organ involvement, like thrombocytopenia, is still unclear, and studies are showing conflicting results. It is worth mentioning that large longitudinal cohort studies describe three different patterns of the disease course: relapsing-remitting (which is the most commonly seen), the chronically active (where patients don’t get into periods of remission) and the monophasic lupus (where patients have one initial flare and no relapses afterwards).13 41 Separating patients in sustained remission from the relapsing-remitting group and the monophasic group can add precision in identifying the predictive factors of long-term remission. Conclusion Long-term remission is the ultimate goal in the management of SLE. Although we now have a standardised definition of what remission should be, there remain a number of limitations in our analysis. In particular, biases still exist due to the subjective rating of the PGA, the heterogeneity of assays measuring serological activity and the attitude of prescribers towards stopping SLE-specific medication. This is shown through the large range of prevalences of remission across different cohorts and explains the difficulty in identifying the predictive factors of sustained remission. There is an urgent need to find objective biological or immunological markers that better define patients in long-term remission and potentially help prescribers with the decision of stopping or weaning down SLE-specific medication. Supplementary material Footnotes Funding: RA is supported by the National Institute of Health and the Rheumatology Discretionary Fund University College London Charity. AR is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Data availability statement No data are available. References Associated Data Supplementary Materials Data Availability Statement No data are available.